Kolovou Genovefa D, Anagnostopoulou Katherine K, Salpea Klelia D, Panagiotakos Demosthenes B, Hoursalas Ioannis S, Cariolou Marios A, Koniavitou Katerina, Cokkinos Dennis V
Onassis Cardiac Surgery Center, 356 Sygrou Ave, 176 74 Athens, Greece.
Ann Clin Lab Sci. 2005 Autumn;35(4):391-6.
Apolipoprotein E (apo E) plays an important role in lipid metabolism and its polymorphism may be a risk determinant of coronary heart disease (CHD). Since evidence suggested a gender-specific effect of apo E polymorphism, we studied the influence of gender-specific interaction of the polymorphism on CHD. From a total of 463 Greek Caucasians (314 men and 149 postmenopausal women) with angiographically documented CHD, we selected 79 women (68+/- 9 yr old) and 79 men (66+/- 9 yr old) who were matched for clinical characteristics. Apo E genotyping was performed by PCR and RFLP analysis. Biochemical parameters were also measured. The results were as follows: the E3/3 genotype occurred in 78.5% of the patients, followed by E3/4, E2/3, E2/4, and E4/4 genotypes, which occurred in 9.5%, 9.5%, 1.9%, and 0.6% of the patients, respectively. No significant differences were observed in the apo E allele or apo E genotype distributions between the matched Greek men and women with CHD. The E3/3 men patients were more frequently part of a family with a history of CHD, compared to women (p=0.035).
载脂蛋白E(apo E)在脂质代谢中起重要作用,其多态性可能是冠心病(CHD)的风险决定因素。由于有证据表明apo E多态性存在性别特异性效应,我们研究了该多态性的性别特异性相互作用对冠心病的影响。在463名经血管造影证实患有冠心病的希腊白种人(314名男性和149名绝经后女性)中,我们选择了79名女性(68±9岁)和79名男性(66±9岁),他们在临床特征上相匹配。通过聚合酶链反应(PCR)和限制性片段长度多态性(RFLP)分析进行apo E基因分型。还测量了生化参数。结果如下:E3/3基因型出现在78.5%的患者中,其次是E3/4、E2/3、E2/4和E4/4基因型,分别出现在9.5%、9.5%、1.9%和0.6%的患者中。在匹配的患有冠心病的希腊男性和女性之间,未观察到apo E等位基因或apo E基因型分布的显著差异。与女性相比,E3/3男性患者更常来自有冠心病家族史的家庭(p = 0.035)。